The user experienced varying results with different hair loss treatments, including finasteride, minoxidil, RU58841, and dutasteride, with recent increased shedding after switching to a higher dose of dutasteride. They suspect the shedding is due to the dutasteride dose increase and question the effectiveness of dutasteride tablets from India.
RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.
The post and conversation discuss the effectiveness of pyrilutamide for hair loss, with comparisons to finasteride and RU58841. Users express skepticism due to failed trials and high costs, with some waiting for more data before trying pyrilutamide.
The conversation discusses managing gynecomastia symptoms potentially caused by finasteride use, with treatments including reducing finasteride dosage, using DIM, ashwagandha, tamoxifen, epistane, and arimistane. Users share experiences and advice on balancing testosterone and estrogen levels to address symptoms.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
Dutasteride users have mixed results in hair loss treatment, with some experiencing improvements and others worsening. Some report metabolic changes like weight gain or diabetes, while others have no significant side effects.
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
A 23-year-old male used 1mg finasteride and topical minoxidil for 90 days, experiencing hair growth and side effects like watery semen and lethargy. He advises continuing medication for hair growth and adopting healthy habits.
The conversation discusses using NAC (N-Acetyl Cysteine) alongside minoxidil and finasteride for hair loss, with some users noting potential hairline improvement and increased energy. The original poster reduced their finasteride dosage due to mental decline and anxiety, and while NAC's effects on hair are anecdotal, it is considered low-risk with other health benefits.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
A user reported using 1.25mg finasteride daily for 9 months with positive hair growth results and increased libido but slower beard growth. Other users commented on the appearance of straightened vs. natural curly hair and potential hair damage from straightening.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
A user is seeking feedback on a homemade topical finasteride formula for hair loss, consisting of 7.5 mg of finasteride, propylene glycol, ethanol, and distilled water. They aim to achieve a 0.0125% solution by applying 2 ml daily.
The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.
The conversation discusses adding either RU58841 or pyrilutamide to a hair loss treatment regimen that already includes oral dutasteride and oral minoxidil. RU58841 is considered the stronger anti-androgen but may have more side effects.
A user ordered H&W's 1.25% Topical Finasteride and is curious about others' experiences and side effects. Another user asked about availability in the US.
Dutasteride tablets from India are significantly cheaper than those from pharmacies, but there are concerns about authenticity and customs issues. The user is also using oral minoxidil, finasteride, and RU58841 for hair loss treatment.
Pyrilutamide is being discussed as a potential hair loss treatment, but opinions are mixed, with some users skeptical about its effectiveness and the company's credibility. Some users report combining pyrilutamide with other treatments like dutasteride and microneedling, noting improvements, while others remain doubtful.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
RU58841 is used by some for hair loss when finasteride and minoxidil are ineffective. Users report mixed results, with some experiencing side effects like chest pain and mood changes.
A new topical finasteride has been approved in France, providing an alternative to oral finasteride with potentially fewer side effects. Users discuss the pros and cons of topical versus oral treatments, with some opting to create their own solutions to save money.
Cetirizine 10mg daily reduced hair shedding by 50% and lessened scalp itchiness. The user is considering long-term use for scalp inflammation and hair loss.
A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.